Your browser is no longer supported. Please, upgrade your browser.
Settings
ZOM Zomedica Pharmaceuticals Corp. daily Stock Chart
ZOM [NYSE]
Zomedica Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-0.12 Insider Own61.49% Shs Outstand94.80M Perf Week-12.43%
Market Cap140.30M Forward P/E- EPS next Y- Insider Trans- Shs Float35.00M Perf Month-19.13%
Income- PEG- EPS next Q- Inst Own3.36% Short Float3.33% Perf Quarter-32.11%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio41.01 Perf Half Y-22.11%
Book/sh0.03 P/B47.74 EPS next Y- ROA- Target Price- Perf Year-34.22%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.08 - 2.98 Perf YTD-25.14%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.34% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low37.04% ATR0.17
Employees20 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)47.26 Volatility14.39% 13.34%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.72 Prev Close1.34
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume28.43K Price1.48
Recom- SMA20-5.73% SMA50-11.09% SMA200-25.07% Volume75,310 Change10.45%
Nov-28-18 09:53AM  Qorvo, Zomedica Tie-Up to Enhance Vet Health with BAW Sensors Zacks +12.34%
Nov-27-18 06:51AM  Zomedica Signs Exclusive Agreement with Qorvo Biotechnologies for Global Veterinary Rights to Diagnostic Point-of-Care Platform GlobeNewswire -10.47%
06:50AM  Zomedica Announces $10 Million Private Offering of Common Shares GlobeNewswire
Nov-26-18 07:25AM  Analysis: Positioning to Benefit within Dominion Energy Midstream Partners, LP, Blue Capital Reinsurance, CRH Medical, Friedman Industries, CM Finance, and Zomedica Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +11.69%
Nov-13-18 04:47PM  Zomedica Pharmaceuticals Corp. Announces Third Quarter 2018 Financial Results GlobeNewswire -5.17%
Nov-12-18 04:30PM  Zomedica Pharmaceuticals Corp. to Present at Jefferies 2018 London Healthcare Conference and LD Micro Main Event XI GlobeNewswire
Oct-16-18 09:00AM  SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp. ACCESSWIRE
Sep-18-18 06:55AM  Zomedica Pharmaceuticals Corp. to Present at LD Micro NYC Summit and Cantor 2018 Global Healthcare Conference GlobeNewswire
Aug-15-18 04:15PM  Zomedica Announces 2018 Annual Meeting Results GlobeNewswire
Aug-09-18 04:01PM  Zomedica Pharmaceuticals Corp. Announces Second Quarter 2018 Financial Results GlobeNewswire
Jun-28-18 08:57PM  Zomedica Announces Interim Closing and Extension of Its Private Offering of Common Shares GlobeNewswire
Jun-25-18 05:59PM  Zomedica Joins Russell 3000 and Russell Microcap® Indexes GlobeNewswire -15.77%
Jun-19-18 06:54AM  Zomedica Provides Product Development Update GlobeNewswire
Jun-14-18 06:15PM  Zomedica Announces Changes to Commercialization Leadership Team GlobeNewswire
May-15-18 04:06PM  Zomedica Pharmaceuticals Corp. Announces First Quarter 2018 Financial Results GlobeNewswire
04:01PM  Zomedica Announces Up to $10 Million Private Offering of Common Shares GlobeNewswire
May-14-18 07:30AM  Wired News Zomedica Inks Deal with Seraph to Develop and Market Seraphs Novel Pathogen Detection System for Veterinarians ACCESSWIRE -5.00%
May-10-18 06:55AM  Zomedica Signs Agreement With Seraph Biosciences for Innovative Veterinary Point-of-Care Diagnostic GlobeNewswire
May-07-18 06:55AM  Zomedica to Present at 2018 Disruptive Growth & Healthcare Conference GlobeNewswire
Mar-26-18 09:00AM  SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) ACCESSWIRE
Mar-07-18 06:55AM  Zomedica to Present at 30th Annual ROTH Conference GlobeNewswire
Feb-28-18 04:11PM  Zomedica Pharmaceuticals Corp. Announces Year End 2017 Financial Results GlobeNewswire
Feb-20-18 06:55AM  Zomedica to Participate in the Bank of America Merrill Lynch Animal Health Summit GlobeNewswire
Dec-01-17 09:00AM  SeeThruEquity Initiates Coverage on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) with a Price Target of $3.24 ACCESSWIRE -6.90%
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.